Among patients with CKD stage 3 or higher, the mean estimated glomerular filtration rate remained stable during the 12 months following thermal ablation for localized renal cell carcinoma.
Salvage cryotherapy is emerging as a viable local treatment option for prostate cancer that recurs following radiation treatment.
In a propensity score-based study, prostate cryoablation added to androgen deprivation therapy (ADT) improved failure-free survival and survival without castration-resistant disease compared with ADT alone.
In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.
Cryoablation also cuts the need for opioids at 24 hours post-treatment and at 3 months.
Oncologic outcomes are similar for focal and total cryoablation for localized prostate cancer, but patients report significantly better sexual function after focal cryoablation.
The recurrence group had significantly larger tumors than the no-recurrence group.
A PSA nadir below 0.4 ng/mL offers the best long-term biochemical progression-free survival, study shows.
Men who underwent whole-gland cryoablation had an estimated 5-year biochemical progression-free survival rate of 59.1%.
Study reveals comparable rates of freedom from biochemical failure at 5 years.
